

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

AMLODIPINE SUSPENSION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AMLODIPINE	KATERZIA	45864		GPI-10	
BENZOATE				(3400000308)	

GUIDELINES FOR USE

1. Is the patient unable to swallow oral amlodipine tablets at prescribed dose?

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of 10mL per day. If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **AMLODIPINE SUSPENSION (Katerzia)** requires the following rule(s) be met for approval:

A. You are unable to swallow oral amlodipine tablets at prescribed dose

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Katerzia.

REFERENCES

 Katerzia [Prescribing Information]. Greenwood Village, CO: Silvergate Pharmaceuticals, Inc., July 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created: 02/20

Commercial Effective: 04/01/20 Client Approval: 02/20 P&T Approval: 01/20

Copyright © 2020 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

2/28/2020 Page 1 of 1